Drug Trial Radar · NCT07873645
Study of UBT37034 Injection
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of UBT37034 for injection in participants who have obesity or are overweight. The main purpose is to learn more about the safety, tolerability, drug concentration, drug action and immune response of repeated UBT37034 administration. This is a single-center, randomized, double-blind, placebo-controlled study with multiple ascending doses. A total of 40 participants will be enrolled in 4 different dose groups. Participants will receive UBT37034 or placebo in an 8:2 random ratio with dose titration. The study will last up to 24 weeks and includes screening, treatment and safety follow-up periods.
Conditions
- Overweight , Obesity
Interventions
UBT37034Drug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Baseline to Week23
- Change from baseline in physical examinationsTime frame: Baseline to Week 23
- Change from baseline in body temperatureTime frame: Baseline to Week 23
- Change from baseline in pulse rateTime frame: Baseline to Week 23
- Change from baseline in blood pressureTime frame: Baseline to Week 23
- Change from baseline in ECG QTcF intervalTime frame: Baseline to Week 23
- Change from baseline in ECG RR intervalTime frame: Baseline to Week 23
- Change from baseline in ECG heart rateTime frame: Baseline to Week 23
- Change from baseline in PHQ-9 total scoreTime frame: Baseline to Week 23
- Change from baseline in C-SSRS scoreTime frame: Baseline to Week 23
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.